Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Conjunctivitis
Intervention: olopatadine 0.2% (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Alcon Research Official(s) and/or principal investigator(s):
Stella Robertson, Study Director, Affiliation: Study Director
Summary
The purpose of this study is to demonstrate that Olopatadine 0. 2% is superior to vehicle in
the treatment of the signs and symptoms associated with allergic conjunctivitis or
rhinoconjunctivitis.
Clinical Details
Official title: A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Daily signs and symptoms scores during the 14 days of peak pollen
Secondary outcome: Patients with daily signs and symptoms scores of zero during the 14 days of peak pollen
Eligibility
Minimum age: 10 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass
antigen challenge reaction (skin test), and a positive response to grass in the
Conjunctival Allergen Challenge (CAC) model
Exclusion Criteria:
- Under 10 years of age
Locations and Contacts
Alcon Research, Ltd., Fort Worth, Texas 76134, United States
Additional Information
Starting date: August 2006
Last updated: June 11, 2008
|
